FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2137979737> ?p ?o ?g. }

• W2137979737 endingPage "614" @default.
• W2137979737 startingPage "608" @default.
• W2137979737 abstract "Purpose of review Avoiding immune destruction is one emerging hallmark of cancer, including glioblastoma. The number of immunotherapy approaches to fight glioblastoma is growing. Here, we review the recent progress in four main areas: dendritic cell immunotherapy, peptide vaccination, chimeric antigen receptors and immune checkpoints. Recent findings We and others are using dendritic cells to present glioblastoma antigens (whole tumor lysate) to the immune system; our initial data indicate that clinical benefit is associated to increased presence of natural killer cells in the periphery. A pilot study loading dendritic cells with glioblastoma stem-like cells will start soon. Peptide vaccination targeting the epidermal growth factor receptor variant III (EGFRvIII) epitope, present in 25% of glioblastomas, is ongoing. Intriguing results have been obtained by vaccination with three other peptides in pediatric gliomas. Another clinical trial is targeting EGFRvIII by adoptive cell transfer of chimeric antigen receptor. This exciting technology could be suited for a number of other potential epitopes discovered through next-generation sequencing. Finally, antibodies against the immune checkpoints cytotoxic T lymphocyte antigen-4 and programmed cell death-1, which demonstrated efficacy in advanced melanomas, will be used in novel trials for recurrent glioblastoma. Summary In all these studies attention to novel side-effects and to MRI as immunological follow-up to distinguish progression or pseudoprogression will be of critical relevance." @default.
• W2137979737 created "2016-06-24" @default.
• W2137979737 creator A5036842630 @default.
• W2137979737 creator A5047711662 @default.
• W2137979737 date "2014-11-01" @default.
• W2137979737 modified "2023-10-12" @default.
• W2137979737 title "Perspectives for immunotherapy in glioblastoma treatment" @default.
• W2137979737 cites W1970976147 @default.
• W2137979737 cites W1972252386 @default.
• W2137979737 cites W1996145004 @default.
• W2137979737 cites W2004818773 @default.
• W2137979737 cites W2005008347 @default.
• W2137979737 cites W2013020286 @default.
• W2137979737 cites W2015085911 @default.
• W2137979737 cites W2017277108 @default.
• W2137979737 cites W2023233297 @default.
• W2137979737 cites W2026938154 @default.
• W2137979737 cites W2031108286 @default.
• W2137979737 cites W2034751554 @default.
• W2137979737 cites W2049429882 @default.
• W2137979737 cites W2053393698 @default.
• W2137979737 cites W2056255115 @default.
• W2137979737 cites W2066671159 @default.
• W2137979737 cites W2085117989 @default.
• W2137979737 cites W2097995306 @default.
• W2137979737 cites W2098414192 @default.
• W2137979737 cites W2100004531 @default.
• W2137979737 cites W2100158834 @default.
• W2137979737 cites W2105400883 @default.
• W2137979737 cites W2107484016 @default.
• W2137979737 cites W2110509194 @default.
• W2137979737 cites W2111511846 @default.
• W2137979737 cites W2111988427 @default.
• W2137979737 cites W2113249787 @default.
• W2137979737 cites W2114147900 @default.
• W2137979737 cites W2116979976 @default.
• W2137979737 cites W2117692326 @default.
• W2137979737 cites W2118241155 @default.
• W2137979737 cites W2118323175 @default.
• W2137979737 cites W2118982164 @default.
• W2137979737 cites W2121362686 @default.
• W2137979737 cites W2123363005 @default.
• W2137979737 cites W2124513722 @default.
• W2137979737 cites W2126072734 @default.
• W2137979737 cites W2131714126 @default.
• W2137979737 cites W2140828776 @default.
• W2137979737 cites W2143163879 @default.
• W2137979737 cites W2143753538 @default.
• W2137979737 cites W2152283027 @default.
• W2137979737 cites W2155599713 @default.
• W2137979737 cites W2209812019 @default.
• W2137979737 doi "https://doi.org/10.1097/cco.0000000000000135" @default.
• W2137979737 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/25210870" @default.
• W2137979737 hasPublicationYear "2014" @default.
• W2137979737 type Work @default.
• W2137979737 sameAs 2137979737 @default.
• W2137979737 citedByCount "25" @default.
• W2137979737 countsByYear W21379797372015 @default.
• W2137979737 countsByYear W21379797372016 @default.
• W2137979737 countsByYear W21379797372017 @default.
• W2137979737 countsByYear W21379797372018 @default.
• W2137979737 countsByYear W21379797372020 @default.
• W2137979737 countsByYear W21379797372021 @default.
• W2137979737 countsByYear W21379797372022 @default.
• W2137979737 countsByYear W21379797372023 @default.
• W2137979737 crossrefType "journal-article" @default.
• W2137979737 hasAuthorship W2137979737A5036842630 @default.
• W2137979737 hasAuthorship W2137979737A5047711662 @default.
• W2137979737 hasConcept C147483822 @default.
• W2137979737 hasConcept C154317977 @default.
• W2137979737 hasConcept C195616568 @default.
• W2137979737 hasConcept C202751555 @default.
• W2137979737 hasConcept C203014093 @default.
• W2137979737 hasConcept C2777701055 @default.
• W2137979737 hasConcept C2778170410 @default.
• W2137979737 hasConcept C2778227246 @default.
• W2137979737 hasConcept C2780674031 @default.
• W2137979737 hasConcept C3875195 @default.
• W2137979737 hasConcept C502942594 @default.
• W2137979737 hasConcept C55493867 @default.
• W2137979737 hasConcept C71924100 @default.
• W2137979737 hasConcept C86803240 @default.
• W2137979737 hasConcept C8891405 @default.
• W2137979737 hasConceptScore W2137979737C147483822 @default.
• W2137979737 hasConceptScore W2137979737C154317977 @default.
• W2137979737 hasConceptScore W2137979737C195616568 @default.
• W2137979737 hasConceptScore W2137979737C202751555 @default.
• W2137979737 hasConceptScore W2137979737C203014093 @default.
• W2137979737 hasConceptScore W2137979737C2777701055 @default.
• W2137979737 hasConceptScore W2137979737C2778170410 @default.
• W2137979737 hasConceptScore W2137979737C2778227246 @default.
• W2137979737 hasConceptScore W2137979737C2780674031 @default.
• W2137979737 hasConceptScore W2137979737C3875195 @default.
• W2137979737 hasConceptScore W2137979737C502942594 @default.
• W2137979737 hasConceptScore W2137979737C55493867 @default.
• W2137979737 hasConceptScore W2137979737C71924100 @default.
• W2137979737 hasConceptScore W2137979737C86803240 @default.
• W2137979737 hasConceptScore W2137979737C8891405 @default.

• next